372 related articles for article (PubMed ID: 22456299)
1. Cost comparison of outpatient treatment with granulocyte colony-stimulating factors (G-CSF) in Germany.
Hadji P; Kostev K; Schröder-Bernhardi D; Ziller V
Int J Clin Pharmacol Ther; 2012 Apr; 50(4):281-9. PubMed ID: 22456299
[TBL] [Abstract][Full Text] [Related]
2. Effectiveness of biosimilar filgrastim vs. original granulocyte colony-stimulating factors in febrile neutropenia prevention in breast cancer patients.
Puértolas I; Frutos Pérez-Surio A; Alcácera MA; Andrés R; Salvador MDT
Eur J Clin Pharmacol; 2018 Mar; 74(3):315-321. PubMed ID: 29152672
[TBL] [Abstract][Full Text] [Related]
3. Comparative effectiveness of granulocyte colony-stimulating factors to prevent febrile neutropenia and related complications in cancer patients in clinical practice: A systematic review.
Mitchell S; Li X; Woods M; Garcia J; Hebard-Massey K; Barron R; Samuel M
J Oncol Pharm Pract; 2016 Oct; 22(5):702-16. PubMed ID: 26769697
[TBL] [Abstract][Full Text] [Related]
4. G-CSF: filgrastim, lenograstim and biosimilars.
Welte K
Expert Opin Biol Ther; 2014 Jul; 14(7):983-93. PubMed ID: 24707817
[TBL] [Abstract][Full Text] [Related]
5. Impact of Guidance on the Prescription Patterns of G-CSFs for the Prevention of Febrile Neutropenia Following Anticancer Chemotherapy: A Population-Based Utilization Study in the Lazio Region.
Trotta F; Mayer F; Mecozzi A; Amato L; Addis A
BioDrugs; 2017 Apr; 31(2):117-124. PubMed ID: 28353170
[TBL] [Abstract][Full Text] [Related]
6. Pegfilgrastim prophylaxis is associated with a lower risk of hospitalization of cancer patients than filgrastim prophylaxis: a retrospective United States claims analysis of granulocyte colony-stimulating factors (G-CSF).
Naeim A; Henk HJ; Becker L; Chia V; Badre S; Li X; Deeter R
BMC Cancer; 2013 Jan; 13():11. PubMed ID: 23298389
[TBL] [Abstract][Full Text] [Related]
7. Potential cost savings from chemotherapy-induced febrile neutropenia with biosimilar filgrastim and expanded access to targeted antineoplastic treatment across the European Union G5 countries: a simulation study.
Sun D; Andayani TM; Altyar A; MacDonald K; Abraham I
Clin Ther; 2015 Apr; 37(4):842-57. PubMed ID: 25704107
[TBL] [Abstract][Full Text] [Related]
8. Comparative cost-efficiency across the European G5 countries of various regimens of filgrastim, biosimilar filgrastim, and pegfilgrastim to reduce the incidence of chemotherapy-induced febrile neutropenia.
Aapro M; Cornes P; Abraham I
J Oncol Pharm Pract; 2012 Jun; 18(2):171-9. PubMed ID: 21610020
[TBL] [Abstract][Full Text] [Related]
9. Biosimilar G-CSF versus filgrastim and lenograstim in healthy unrelated volunteer hematopoietic stem cell donors.
Farhan R; Urbanowska E; Zborowska H; Król M; Król M; Torosian T; Piotrowska I; Bogusz K; Skwierawska K; Wiktor-Jędrzejczak W; Snarski E
Ann Hematol; 2017 Oct; 96(10):1735-1739. PubMed ID: 28801752
[TBL] [Abstract][Full Text] [Related]
10. A systematic review of available clinical evidence - filgrastim compared with lenograstim.
Sourgens H; Lefrère F
Int J Clin Pharmacol Ther; 2011 Aug; 49(8):510-8. PubMed ID: 21781651
[TBL] [Abstract][Full Text] [Related]
11. [Pegfilgrastim vs filgrastim in primary prophylaxis of febrile neutropenia in patients with breast cancer after chemotherapy: a cost-effectiveness analysis for Germany].
Sehouli J; Goertz A; Steinle T; Dubois R; Plesnila-Frank C; Lalla A; von Minckwitz G
Dtsch Med Wochenschr; 2010 Mar; 135(9):385-9. PubMed ID: 20180162
[TBL] [Abstract][Full Text] [Related]
12. Management and cost analysis of cancer patients treated with G-CSF: a cohort study based on the French national healthcare insurance database.
Tilleul P; Jacot W; Emery C; Lafuma A; Gourmelen J
J Med Econ; 2017 Dec; 20(12):1261-1267. PubMed ID: 28795868
[TBL] [Abstract][Full Text] [Related]
13. A Comparison of Proposed Biosimilar LA-EP2006 and Reference Pegfilgrastim for the Prevention of Neutropenia in Patients With Early-Stage Breast Cancer Receiving Myelosuppressive Adjuvant or Neoadjuvant Chemotherapy: Pegfilgrastim Randomized Oncology (Supportive Care) Trial to Evaluate Comparative Treatment (PROTECT-2), a Phase III, Randomized, Double-Blind Trial.
Blackwell K; Donskih R; Jones CM; Nixon A; Vidal MJ; Nakov R; Singh P; Schaffar G; Gascón P; Harbeck N
Oncologist; 2016 Jul; 21(7):789-94. PubMed ID: 27091420
[TBL] [Abstract][Full Text] [Related]
14. A retrospective study of patients' out-of-pocket costs for granulocyte colony-stimulating factors.
Tomic K; Long S; Li X; Fu AC; Yu TC; Barron R
J Oncol Pharm Pract; 2013 Dec; 19(4):328-37. PubMed ID: 23353712
[TBL] [Abstract][Full Text] [Related]
15. Biosimilars of filgrastim in autologous stem cell transplant: reduction in granulocyte-colony stimulating factor costs, but similar effects on bone marrow recovery.
Ianotto JC; Ngo Sack F; Couturier MA; Tempescul A; Mugnier N; Delepine P; Guillerm G; Berthou C
Leuk Lymphoma; 2014 Jan; 55(1):74-7. PubMed ID: 23566160
[TBL] [Abstract][Full Text] [Related]
16. Cost comparison of filgrastim versus pegfilgrastim and pegfilgrastim biosimilars for inpatient prophylaxis of febrile neutropenia.
Singer K; Forshay CM; Kennerly-Shah J
J Oncol Pharm Pract; 2023 Oct; 29(7):1695-1701. PubMed ID: 36544396
[TBL] [Abstract][Full Text] [Related]
17. Recombinant granulocyte colony-stimulating factor (rG-CSF) in the management of neutropenia induced by anthracyclines and ifosfamide in patients with soft tissue sarcomas (NEUSAR).
Bongiovanni A; Monti M; Foca F; Recine F; Riva N; Di Iorio V; Liverani C; De Vita A; Miserocchi G; Mercatali L; Amadori D; Ibrahim T
Support Care Cancer; 2017 Jan; 25(1):111-117. PubMed ID: 27568305
[TBL] [Abstract][Full Text] [Related]
18. Frequency of febrile neutropenia in breast cancer patients receiving epirubicin and docetaxel/paclitaxel with colony-stimulating growth factors: a comparison of filgrastim or lenograstim with pegfilgrastim.
Schippinger W; Holub R; Dandachi N; Bauernhofer T; Samonigg H
Oncology; 2006; 70(4):290-3. PubMed ID: 16899982
[TBL] [Abstract][Full Text] [Related]
19. Economic analysis of prophylactic pegfilgrastim in adult cancer patients receiving chemotherapy.
Eldar-Lissai A; Cosler LE; Culakova E; Lyman GH
Value Health; 2008; 11(2):172-9. PubMed ID: 18380630
[TBL] [Abstract][Full Text] [Related]
20. Cost effectiveness of pegfilgrastim versus filgrastim after high-dose chemotherapy and autologous stem cell transplantation in patients with lymphoma and myeloma: an economic evaluation of the PALM Trial.
Perrier L; Lefranc A; Pérol D; Quittet P; Schmidt-Tanguy A; Siani C; de Peretti C; Favier B; Biron P; Moreau P; Bay JO; Lissandre S; Jardin F; Espinouse D; Sebban C
Appl Health Econ Health Policy; 2013 Apr; 11(2):129-38. PubMed ID: 23435861
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]